At Hart Biologicals, we have a proud company history dating back almost 20 years. From a humble Hartlepool start-up, we have grown into a thriving local biomedical company with a global reach. This didn’t happen overnight, and becoming global exporters took a lot of hard work and dedication. Luckily, we have a fantastic team of scientific experts behind us to turn Hart Biologicals' vision into a reality.
As specialists in haemostasis testing, we work with several of the top 10 leading haemostasis testing companies in the world. We supply 50% of the global reagents for a prominent American in vitro diagnostics company, as well as supporting international quality control organisations like NEQAS – which is an industry gold standard.
We currently export to 34 countries across the globe. Year-on-year, up to 80% of our £2.6m annual turnover is driven by export sales, so our global operations remain a key strategic priority for us. Our products are registered internationally, and some of our flagship projects including our Thrombi-Stat MC1/4/10, CLOtest and Factor deficient plasmas, can be found in countries across South-East Asia and South America, to Thailand & Turkey.
Our products and services have a genuinely global reach, and we work with an international network of distributors across the world. As a result, we’ve accumulated an impressive trophy cabinet of awards over the years, being recognised on multiple occasions at the North East Business Awards and the Made in the North East Awards in their innovation and export categories. We’re proud to be part of the North East’s global export success story. An export-led region, and the only net-exporting region of the UK, the North East contributes an annual £13.2 billion to the national market.
Over recent months, ongoing Brexit negotiations and COVID-19 related disruption have generated added pressure for businesses. However, one of our great strengths in the North East is our position as a solution-driven region. The Chancellor, Rishi Sunak, recently highlighted the roles of innovation, life sciences and exports in driving the post-COVID-19 recovery. This plays to our region’s natural strengths with its wealth of world-class life science talent, strong export record and integrated innovation pipelines through its leading universities. We’re well placed to be part of the post-Brexit, post-COVID-19, economic recovery in the North East and globally. The region has a bright future and focussing on our core strengths will be vital to remaining competitive and staying ahead of the game.
At Hart Biologicals, we’re not resting on our laurels. We have ambitious plans to elevate our products, services and ourselves [link to page], as we enter a bright new decade full of opportunities. At a time when the North East’s future trading relationship with the rest of the world remains uncertain, we need to nurture our world-class export talent to drive our future success. Our team remained focused on continuing our exports success by identifying new opportunities in new and emerging markets, and addressing the global needs of the haemostasis market, as only we at Hart Biologicals can.